Two senior doctors who co-founded Fullerton Healthcare Corporation in Singapore have been ordered to pay substantial fines following guilty pleas to falsification of accounts charges. Daniel Chan Pai Sheng and Michael Tan Kim Song, both 52 years old, received combined penalties of S$160,000 on July 10 for their roles in a scheme that inflated entertainment expenses by more than S$211,000 over several years. The case highlights vulnerabilities in corporate expense controls at growth-stage healthcare companies and raises questions about internal governance structures that allowed such systematic misrepresentation to persist undetected.
The falsified claims were not motivated by direct financial gain for the two defendants. Instead, the inflated sums were intended to benefit Collin Chiew, a 58-year-old executive who previously served as chief executive of insurance broker Aon Singapore from January 2015 to July 2018. Court documents indicate that Chiew requested financial assistance from Chan in 2015, claiming he needed money for his children's education and home expenses. This personal request became the catalyst for the systematic falsification scheme that would eventually unravel the integrity of FHC's expense records across multiple years and jurisdictions.
Chan bore primary responsibility within the conspiracy and faced the more severe sanctions. He pleaded guilty to five counts of falsification of accounts involving more than S$336,000 in claimed expenses, when actual costs amounted to approximately S$125,000. The magnitude of the discrepancy—more than S$211,000—demonstrates a deliberate and sustained pattern rather than isolated accounting errors or careless record-keeping. His S$135,000 fine reflects the seriousness with which Singapore's courts treat systematic falsification of corporate financial documents. Tan received a lighter penalty of S$25,000 after pleading guilty to a single count of falsification linked to one of Chan's charges, with approximately S$82,000 in false claims against actual expenses of over S$42,000.
The mechanics of the scheme reveal a troubling level of operational sophistication. Beginning around 2015, Chan travelled to Hong Kong approximately twice monthly on business matters related to FHC's regional operations. Before each trip, he would instruct David Sin, a third co-founder who also faces separate charges, to obtain inflated or entirely fabricated receipts from entertainment venues. Another individual, Tei Chu Pink, 46, was systematically responsible for preparing these false documents. The arrangement allowed Chan to collect receipts bearing inflated amounts that bore little relation to actual expenditures—on many occasions, he would pay only a fraction of the claimed amount using personal cash or credit cards, while on other instances, he made no payment whatsoever.
Upon returning to Singapore, Chan would distribute these receipts to relevant personnel within FHC and its subsidiary Fullerton Health China, who would then process them through normal expense reimbursement channels. This process converted false entertainment claims into legitimate company transfers to Chiew. The prosecution demonstrated that Tan possessed knowledge of these arrangements and, in at least one 2016 instance, participated in a three-way conspiracy with Chan and Sin to falsify a specific entertainment claim. The involvement of multiple conspirators and the systematic nature of the operation distinguish this case from spontaneous misconduct and suggest organisational dysfunction at senior management levels.
David Sin, the third co-founder, emerged from earlier court proceedings with a separate resolution. In August 2025, Sin pleaded guilty to six counts of falsification of accounts and received an identical S$160,000 fine, suggesting comparable culpability despite his different charge profile. The parallel sentencing indicates the courts viewed his role as substantially equivalent to Chan's participation, despite the reduced number of specific charges he faced. Sin's involvement in preparing false receipts and his participation in the 2016 conspiracy made him an essential operational component of the scheme.
Crucially, the prosecution moved to discharge the graft charges against both Chan and Tan without acquittal, citing prosecutorial discretion. This legal manoeuvre, which the court granted, preserves the Crown's ability to prosecute these charges in future if new evidence emerges. The decision suggests confidence in the falsification convictions while maintaining flexibility regarding corruption allegations. A discharge without acquittal differs fundamentally from acquittal; it represents a prosecutorial pause rather than a determination of innocence, allowing authorities to reopen investigation into whether the financial assistance to Chiew constituted corrupt inducements or bribes.
The case carries broader implications for corporate governance across Southeast Asia. Healthcare organisations, particularly those involved in insurance claim processing, occupy critical positions in regional financial systems. Fullerton Healthcare's business model—providing medical services through networked practitioners while assisting clients with insurance claims—created multiple touchpoints where falsified documentation could flow undetected through established procedures. The fact that senior founding physicians systematised expense falsification suggests that professional credentials and business ownership do not guarantee ethical conduct or adequate financial controls. Many fast-growing regional healthcare firms may lack the sophisticated compliance infrastructure necessary to detect similar schemes.
For Malaysian business leaders and corporate governance professionals, the Fullerton case underscores the necessity of independent expense verification systems, particularly for international travel and entertainment claims. The company's failure to implement basic reconciliation procedures—comparing claimed amounts against actual invoices or bank records—allowed falsifications to accumulate across multiple years. Regional companies expanding operations across Asia while maintaining relatively informal governance structures face elevated risks of similar misconduct. The Singapore authorities' prosecution demonstrates that even co-founders with substantial reputational stakes will face enforcement action when systematic falsification occurs.
The distinction between the fines imposed and the absence of direct personal enrichment also merits attention. Malaysian corporate boards should recognise that facilitating unauthorised payments to third parties—even when directors personally abstain from direct gain—constitutes serious misconduct warranting board oversight and potentially shareholder action. The case demonstrates that corporate malfeasance often involves complex motivations: Chan and Tan may have believed they were assisting a business contact in genuine financial difficulty, yet their method crossed into systematic falsification of accounts, a criminal violation regardless of underlying intent.
The Fullerton case also reflects Singapore's increasingly robust enforcement approach to white-collar crime. The Corrupt Practices Investigation Bureau's active investigation, the prosecution's willingness to pursue parallel charges across multiple defendants, and the courts' imposition of substantial monetary penalties indicate that regional authorities are prioritising financial crime prosecutions. This enforcement pattern carries implications for Malaysian companies operating across borders or maintaining complex corporate structures. Directors and senior managers face genuine exposure if they participate in schemes involving falsified documentation, even when motivated by sympathy for colleagues or business considerations rather than personal enrichment.
Moving forward, the case serves as a cautionary marker for healthcare and professional services firms throughout the region. Fullerton Healthcare itself presumably implemented remedial governance measures following the prosecutions, though the impact on the company's market position and stakeholder relationships remains unclear. For competitors and other regional healthcare operators, the lesson involves recognising that inadequate expense controls and informal decision-making structures among co-founders create environments where systematic falsification becomes possible. The substantial fines—S$160,000 each for Chan and Sin, totalling S$135,000 for Chan and S$25,000 for Tan—represent material financial consequences that extend beyond individual defendants to potentially affect company operations, insurance coverage, and reputational standing in increasingly competitive regional healthcare markets.
